References
  1. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455-465.
  2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047
  3. Wurthwein G, Krumpelmann S, Tillmann B, et al. Population pharmacokinetic approach to compare oral and iv administration of etoposide. Anticancer Drugs 1999;10:807-814.
  4. Kebudi R, Corgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-324.
  5. Verschuur A, Heng-Mallard MA, Dory-Lautrec P, et al. Metronomic four-drug regimen has anti-tumor activity in pediatric low-grade glioma; the results of a phase II clinical trial. Front Pharmacol 2018;27:00950.
  6. Heng-Mallard MA, Verschuur A, Aschero A, et al. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. Pediatr Blood Cancer 2019;66:e27693.
  7. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006;29:308-313.
  8. Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 2012;82:249-260.
  9. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.
  10. Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2014;61:636-642.
  11. Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: A snapshot. Pediatr Blood Cancer 2019;66:e27811.
  12. Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors. A randomized clinical trial. Jama Oncol 2017;3:1222-1227.
  13. Malik OS, Raina V, Andre N, et al. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol 2014;4:76.
  14. Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 – Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 2016;62:138-145.
  15. Common Terminology Criteria for Adverse Events (CTCAE) Version5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
  16. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452-458.
  17. Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019;20:1566-1575.
  18. Kerbel RS, Shaked Y. Therapy-activated stromal cells can dictate tumor fate. J Exp Med 2016;213:2831-2833.
  19. Saiki-Craghill S. The children’s sentinels: mothers and their relationships with health professionals in the context of Japanese health care. Soc Sci Med 1997;44:291-300.
  20. Mayer DK, Parsons SK, Terrin N, et al. School re-entry after a cancer diagnosis: physician attitudes about truth telling and information sharing. Child Care Health Dev 2005;31:355-63.
  21. Senerchia A, Macedo CR, Ferman S, et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment. Cancer 2017;123:1003-1010.
  22. Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Societe Francaise des Cancers et leucemies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer 2012;48:2409-2416.
  23. Choi DK, Helenowski I, Hijiya N, et al. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer 2014;135:1764-1773.
  24. GröbnerSN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature 2018;555:321-327.
  25. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk blastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011;11:21.